A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer
Status:
Completed
Trial end date:
2019-05-20
Target enrollment:
Participant gender:
Summary
TRX-818 is a new small molecule chemical entity being developed as a potential anti-cancer
therapeutic by TaiRx, Inc. TRX-818 is a potent anti-cancer agent in numerous human cancer
cell lines. The objectives of this study are to determine the safety profile of TRX-818
including identification of dose limiting toxicity (DLT) and maximum tolerated dose (MTD) and
determine the recommended dose and regimen(s) to initiate Phase 2.